Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
MICROLITE vs CALCIUM CHLORIDE 10%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
MICROLITE (lithium citrate) is not a standard drug; no specific mechanism available. Assuming a hypothetical electrolyte supplement, it would act by replacing essential electrolytes.
Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.
Electrolyte replenishment,Hypokalemia,Hypomagnesemia
Emergency treatment of hypocalcemic tetany,Cardiac resuscitation in the presence of hyperkalemia or hypocalcemia,Treatment of calcium channel blocker overdose,Treatment of magnesium sulfate overdose,Management of acute hypermagnesemia,Used in cardiac surgery to reverse citrate anticoagulation
1 tablet orally every 8 hours with or without food.
IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.
Terminal elimination half-life is 12–15 hours in healthy adults, allowing twice-daily dosing. Half-life may be prolonged in renal impairment (up to 30 hours in severe cases).
Terminal half-life ~4-6 hours for rapid distribution phase; prolonged in renal impairment (up to 24-48 hours).
Not metabolized; excreted unchanged by kidneys.
Calcium chloride is not metabolized; it is excreted primarily in the urine with reabsorption regulated by the kidneys and parathyroid hormone.
Renal excretion accounts for approximately 70% of the dose, primarily as unchanged drug. Fecal elimination constitutes about 30%, with a minor contribution from biliary excretion (<10%).
Primarily renal (>80% as ionized calcium); minor fecal elimination (10-20%) via endogenous secretion; negligible biliary excretion.
98% bound to serum albumin. Minimal binding to alpha-1-acid glycoprotein.
Approximately 45-50% bound to albumin; 10-15% complexed with citrate, phosphate, or bicarbonate.
0.15–0.20 L/kg, indicating distribution primarily into extracellular fluid. Does not extensively penetrate tissues or cross the blood-brain barrier significantly.
0.3-0.4 L/kg (primarily extracellular fluid). Increased in hypocalcemia or hypoalbuminemia.
Oral: 90% (well absorbed, minimal first-pass metabolism). Intramuscular: 100% (complete absorption).
IV/IO: 100%. Not administered orally for systemic effect due to GI irritation and poor absorption; oral bioavailability is negligible (<1%) if ingested.
GFR 30-50 m L/min: 1 tablet every 12 hours; GFR 15-29 m L/min: 1 tablet every 24 hours; GFR <15 m L/min: contraindicated.
e GFR <30 m L/min: Use with caution, reduce dose by 50% and monitor serum calcium closely; e GFR <15 m L/min: Avoid use if possible, if necessary use lowest effective dose with frequent monitoring.
Child-Pugh A: no adjustment; Child-Pugh B: 1 tablet every 12 hours; Child-Pugh C: contraindicated.
No specific dose adjustment required for Child-Pugh class A, B, or C; monitor serum calcium due to potential for altered vitamin D metabolism.
Weight <30 kg: 10 mg/kg/dose orally every 8 hours; Weight ≥30 kg: same as adult dosing.
IV: 10-20 mg/kg of elemental calcium (0.1-0.2 m L/kg of 10% solution) given slowly (not exceeding 0.5 m L/min). Maximum single dose: 500 mg (5 m L). May repeat in 4-6 hours if needed.
No specific dose adjustment required based on age alone; monitor renal function and adjust per renal adjustment guidelines.
Start at lower end of dosing range (e.g., 500 mg IV), administer at a slower rate (over 10-15 minutes) due to higher risk of hypercalcemia and cardiovascular effects; monitor renal function and serum calcium frequently.
None
Rapid intravenous injection may cause cardiac arrest. Avoid extravasation as it causes severe tissue necrosis. Use with extreme caution in patients receiving digitalis glycosides due to risk of arrhythmias.
Use with caution in renal impairment; monitor serum electrolytes; avoid in patients with hyperkalemia or hypermagnesemia.
Administer intravenously only; intramuscular or subcutaneous injection causes severe irritation and necrosis.,Use with caution in patients with renal impairment, sarcoidosis, or hypercalcemia.,Monitor serum calcium levels and electrocardiogram during administration.,Risk of bradycardia and arrhythmias, especially with concurrent digitalis therapy.,Rapid injection may cause vasodilation, hypotension, and cardiac arrest.
Hyperkalemia, hypermagnesemia, severe renal impairment.
Hypercalcemia,Ventricular fibrillation during cardiac arrest (unless due to hypocalcemia),Severe hypercalciuria or calcinosis,Concurrent digitalis therapy (relative, may increase risk of arrhythmias)
Avoid high-potassium foods (e.g., bananas, oranges, spinach, potatoes) unless monitored. Salt substitutes (e.g., KCl) increase hyperkalemia risk. Take with food to minimize GI upset.
Avoid excessive intake of oxalate-rich foods (spinach, rhubarb, beets) and phytate-rich foods (bran, whole grains) as they may bind calcium and reduce absorption. Also limit sodium-containing foods to prevent calcium loss via urine. No direct food interactions with intravenous administration.
MICROLITE (magnesium citrate) is generally considered low risk for teratogenicity. No increased risk of major malformations has been reported in human studies. First trimester: No specific data but theoretical risk minimal due to poor oral absorption. Second/Third trimester: No known adverse fetal effects; used therapeutically for preeclampsia prevention at higher doses (IV magnesium sulfate, not this oral form).
Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calcium is an essential mineral for fetal development; however, high doses may lead to hypercalcemia in the mother and fetus. In the first trimester, no specific teratogenic risk is documented; however, maternal hypercalcemia from excessive supplementation may interfere with placental calcium transport and fetal bone development. In the second and third trimesters, excessive doses may cause fetal hypoparathyroidism, hypercalcemia, and potential neonatal hypocalcemia due to suppression of the fetal parathyroid gland. Use only if clearly needed and with caution.
Magnesium is excreted into breast milk; however, oral magnesium citrate is poorly absorbed. Infant exposure is likely minimal. M/P ratio not established. Use caution with high doses as diarrhea in mother may occur, but breastfeeding is generally considered compatible.
Calcium is excreted into breast milk. The M/P ratio for calcium is approximately 1.0 (range 0.9-1.1) reflecting passive diffusion and active transport. Intravenous calcium chloride administration may transiently increase maternal serum calcium levels, leading to a small increase in milk calcium concentration. However, this is unlikely to cause adverse effects in the breastfed infant. The American Academy of Pediatrics considers calcium supplementation compatible with breastfeeding. Use with caution and monitor infant for signs of hypercalcemia (e.g., constipation, irritability) if high doses are administered.
No dosage adjustment typically required for oral magnesium citrate during pregnancy. However, gastrointestinal absorption may be slightly decreased; no change recommended. Avoid high doses due to risk of maternal diarrhea and electrolyte imbalance.
Pregnancy is associated with increased plasma volume and enhanced renal clearance, potentially lowering serum calcium levels. However, calcium chloride is typically administered intravenously for acute hypocalcemia or cardiac resuscitation; no specific dose adjustments are recommended solely due to pregnancy. Use standard dosing based on the indication and severity of hypocalcemia, with close monitoring of serum calcium to avoid overdosage. The same caution applies: administer slowly (0.5-1 m L/min of 10% solution) and check ECG if rapid infusion.
Microlite is a potassium-magnesium supplement used for electrolyte repletion. Monitor renal function prior to initiation; avoid in severe renal impairment (Cr Cl <30 m L/min). Use cautiously with ACE inhibitors, ARBs, or potassium-sparing diuretics due to hyperkalemia risk. Infuse slowly if intravenous to avoid phlebitis.
Calcium chloride 10% (100 mg/m L) provides 13.6 m Eq/10 m L of calcium. It is highly irritating; administer via central venous line to avoid severe tissue necrosis if extravasation occurs. Do not mix with bicarbonate or phosphate solutions. In cardiac arrest, consider dose of 500-1000 mg IV push (repeat q10min if needed). Contraindicated in digitalis toxicity due to risk of fatal arrhythmias.
Take with food or after meals to reduce gastrointestinal irritation.,Do not crush or chew extended-release tablets; swallow whole.,Report muscle weakness, fatigue, or irregular heartbeat immediately.,Avoid salt substitutes containing potassium unless directed by your healthcare provider.,Store at room temperature away from moisture and heat.
This medication is given intravenously to treat calcium deficiency or certain emergencies.,You may experience a warm sensation, metallic taste, or flushing during injection.,Report any burning, pain, or redness at the injection site immediately.,Avoid taking digoxin (digitalis) unless specifically instructed by your doctor.,Do not stop or change the dose without consulting your healthcare provider.
No interactions on record
"Calcium chloride, an intravenous calcium salt, directly increases serum ionized calcium levels, which can antagonize the pharmacodynamic effects of the calcium channel blocker manidipine. Manidipine inhibits L-type calcium channels in vascular smooth muscle, leading to vasodilation and reduced blood pressure. Elevated extracellular calcium from calcium chloride administration can overcome this blockade, potentially diminishing the antihypertensive efficacy of manidipine and increasing the risk of hypertensive urgency or elevated blood pressure."
"Calcium chloride, a source of calcium ions, can chelate with bisphosphonates such as risedronic acid in the gastrointestinal tract, forming insoluble complexes that reduce the oral absorption of risedronic acid. This interaction may lead to decreased serum concentrations of risedronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption. Patients may experience reduced bone mineral density or increased risk of fractures if the interaction is significant."
"Calcium chloride, a source of calcium ions, can chelate alendronic acid (a bisphosphonate) in the gastrointestinal tract, forming insoluble complexes that reduce the absorption of alendronic acid. This interaction can significantly decrease the systemic bioavailability and serum concentration of alendronic acid, potentially compromising its therapeutic efficacy in preventing bone resorption and treating osteoporosis. Clinically, patients may experience reduced bone mineral density improvement or increased fracture risk if the drugs are co-administered."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about MICROLITE vs CALCIUM CHLORIDE 10%, answered by our medical review team.
MICROLITE is a Electrolyte Supplement that works by MICROLITE (lithium citrate) is not a standard drug; no specific mechanism available. Assuming a hypothetical electrolyte supplement, it would act by replacing essential electrolytes.. CALCIUM CHLORIDE 10% is a Electrolyte Supplement that works by Calcium chloride dissociates to provide calcium ions, which are essential for myocardial contractility, nerve impulse transmission, and blood coagulation. It antagonizes the cardiotoxic effects of hyperkalemia by stabilizing cardiac cell membrane potential.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between MICROLITE and CALCIUM CHLORIDE 10% depend on the specific clinical indication. These are both Electrolyte Supplement agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of MICROLITE is: 1 tablet orally every 8 hours with or without food.. The standard adult dose of CALCIUM CHLORIDE 10% is: IV: 500 mg to 1 g (5-10 m L of 10% solution) administered slowly at a rate not exceeding 0.5-1 m L/min; may be repeated every 1-3 days based on serum calcium levels.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between MICROLITE and CALCIUM CHLORIDE 10% in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. MICROLITE is classified as Category C. MICROLITE (magnesium citrate) is generally considered low risk for teratogenicity. No increased risk of major malformations has been reported in human studies. First trimester: No . CALCIUM CHLORIDE 10% is classified as Category C. Animal reproduction studies have not been conducted with calcium chloride. It is not known whether calcium chloride can cause fetal harm when administered to a pregnant woman. Calc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.